MicroRNAs as outcome predictors in patients with metastatic
colorectal cancer treated with bevacizumab in combination with
FOLFOX

J 2017

MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX

KISS, Igor; Jitka MLČOCHOVÁ; Kamila SOUČKOVÁ; Pavel FABIAN; Alexandr POPRACH et al.

Základní údaje

Originální název

MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX

Autoři

KISS, Igor; Jitka MLČOCHOVÁ; Kamila SOUČKOVÁ ; Pavel FABIAN; Alexandr POPRACH; Jana HALÁMKOVÁ; Marek SVOBODA; Rostislav VYZULA a Ondřej SLABÝ

Vydání

Oncology letters, Athens, Spandidos Publications, 2017, 1792-1074

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.664

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14740/17:00095709

Organizační jednotka

Středoevropský technologický institut

Klíčová slova anglicky

bevacizumab; metastatic colorectal cancer; microRNA; progression-free survival; predictive biomarker

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 3. 2018 15:29, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Bevacizumab is a humanized anti-vascular endothelial growth factor monoclonal antibody, used in combination with a oxaliplatin-based chemotherapy in the treatment of metastatic colorectal cancer (mCRC). The aim of the present study was to identify microRNA (miRNA)-based predictive biomarkers of therapy response in order to avoid unnecessary and costly therapy to non-responding patients. High-throughput miRNA microarray profiling (Affymetrix miRNA array) was performed on a discovery cohort of patients with mCRC. The discovery cohort was (n=20) divided into either responding (n=10) or non-responding (n=10) groups of bevacizumab/5-flourouracil, leucovorin, oxaliplatin (FOLFOX) treatment according to Response Evaluation Criteria in Solid Tumors criteria. Validation of candidate miRNAs was performed on an independent cohort of 41 patients with mCRC using quantitative reverse transcription polymerase chain reaction. Normalized data were subjected to receiver operating characteristic and Kaplan-Meier analyses. In total, 67 miRNAs were identified to be differentially expressed when miRNA expression was compared between responding and non-responding patients to bevacizumab/FOLFOX treatment (P<0.05). A total of 7 miRNAs were chosen for independent validation, which confirmed significantly higher expression of miR-92b-3p, miR-3156-5p, miR-10a-5p and miR-125a-5p (P<0.005) in tumor tissue of responding patients compared with non-reponding patients. Using the combination of miRNAs, the present study identified responders to the therapy with sensitivity 82% and specificity 64% (area under the curve = 0.8015). In conclusion, 4 predictive miRNAs associated with progression-free survival (PFS) were identified in patients with mCRC treated with bevacizumab/FOLFOX. Following further independent validations, detection of these miRNA may enable identification of patients with mCRC who may potentially benefit from the therapy.

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

NV16-31765A, projekt VaV

Název: Využití tkáňových/cirkulujících mikroRNA pro predikci léčebné odpovědi a zpřesnění restagingu karcinomu rekta po neoadjuvantní léčbě

Citovat

KISS, Igor; Jitka MLČOCHOVÁ; Kamila SOUČKOVÁ; Pavel FABIAN; Alexandr POPRACH; Jana HALÁMKOVÁ; Marek SVOBODA; Rostislav VYZULA a Ondřej SLABÝ. MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX. Oncology letters. Athens: Spandidos Publications, 2017, roč. 14, č. 1, s. 743-750. ISSN 1792-1074. Dostupné z: https://doi.org/10.3892/ol.2017.6255.

@article{1410005,
   author = {Kiss, Igor and Mlčochová, Jitka and Součková, Kamila and Fabian, Pavel and Poprach, Alexandr and Halámková, Jana and Svoboda, Marek and Vyzula, Rostislav and Slabý, Ondřej},
   article_location = {Athens},
   article_number = {1},
   doi = {https://doi.org/10.3892/ol.2017.6255},
   keywords = {bevacizumab; metastatic colorectal cancer; microRNA; progression-free survival; predictive biomarker},
   language = {eng},
   issn = {1792-1074},
   journal = {Oncology letters},
   title = {MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX},
   url = {https://www.spandidos-publications.com/10.3892/ol.2017.6255},
   volume = {14},
   year = {2017}
}

TY  - JOUR
ID  - 1410005
AU  - Kiss, Igor - Mlčochová, Jitka - Součková, Kamila - Fabian, Pavel - Poprach, Alexandr - Halámková, Jana - Svoboda, Marek - Vyzula, Rostislav - Slabý, Ondřej
PY  - 2017
TI  - MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX
JF  - Oncology letters
VL  - 14
IS  - 1
SP  - 743-750
EP  - 743-750
PB  - Spandidos Publications
SN  - 17921074
KW  - bevacizumab
KW  - metastatic colorectal cancer
KW  - microRNA
KW  - progression-free survival
KW  - predictive biomarker
UR  - https://www.spandidos-publications.com/10.3892/ol.2017.6255
N2  - Bevacizumab is a humanized anti-vascular endothelial growth factor monoclonal antibody, used in combination with a oxaliplatin-based chemotherapy in the treatment of metastatic colorectal cancer (mCRC). The aim of the present study was to identify microRNA (miRNA)-based predictive biomarkers of therapy response in order to avoid unnecessary and costly therapy to non-responding patients. High-throughput miRNA microarray profiling (Affymetrix miRNA array) was performed on a discovery cohort of patients with mCRC. The discovery cohort was (n=20) divided into either responding (n=10) or non-responding (n=10) groups of bevacizumab/5-flourouracil, leucovorin, oxaliplatin (FOLFOX) treatment according to Response Evaluation Criteria in Solid Tumors criteria. Validation of candidate miRNAs was performed on an independent cohort of 41 patients with mCRC using quantitative reverse transcription polymerase chain reaction. Normalized data were subjected to receiver operating characteristic and Kaplan-Meier analyses. In total, 67 miRNAs were identified to be differentially expressed when miRNA expression was compared between responding and non-responding patients to bevacizumab/FOLFOX treatment (P<0.05). A total of 7 miRNAs were chosen for independent validation, which confirmed significantly higher expression of miR-92b-3p, miR-3156-5p, miR-10a-5p and miR-125a-5p (P<0.005) in tumor tissue of responding patients compared with non-reponding patients. Using the combination of miRNAs, the present study identified responders to the therapy with sensitivity 82% and specificity 64% (area under the curve = 0.8015). In conclusion, 4 predictive miRNAs associated with progression-free survival (PFS) were identified in patients with mCRC treated with bevacizumab/FOLFOX. Following further independent validations, detection of these miRNA may enable identification of patients with mCRC who may potentially benefit from the therapy.
ER  -

KISS, Igor; Jitka MLČOCHOVÁ; Kamila SOUČKOVÁ; Pavel FABIAN; Alexandr POPRACH; Jana HALÁMKOVÁ; Marek SVOBODA; Rostislav VYZULA a Ondřej SLABÝ. MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX. \textit{Oncology letters}. Athens: Spandidos Publications, 2017, roč.~14, č.~1, s.~743-750. ISSN~1792-1074. Dostupné z: https://doi.org/10.3892/ol.2017.6255.

Přehled o publikaci